Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14

Sorrento Therapeutics, Inc.

SAN DIEGO, Sept. 8, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D., Chairman, President and CEO, and members of The Sorrento’s executive team will participate on the 20the Morgan Stanley Annual Global Health Conference:

morgan stanley 20the Annual Global Health Conference

  • Location: New York City

  • Dates: September 12 to 14, 2022

  • Company Presentation: September 14, 2022 at 8:00 am Eastern Time

  • CEO Fireside Chat format and available for 1×1 investor meetings

About Sorrento Therapeutics, Inc.

Sorrento is a commercial and clinical-stage biopharmaceutical company developing novel therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. Sorrento’s multimodal, multifaceted approach to fighting cancer is made possible by its broad immuno-oncology platforms, including key assets such as next-generation tyrosine kinase inhibitors (TKIs), fully human antibodies (“G-MAB™ library”) , immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADC”) and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558, COVISHIELD™ and COVIDROPS™; and diagnostic testing solutions, including COVIMARK™.

Sorrento’s commitment to therapies that improve the lives of patients is also demonstrated by our effort to develop a non-opioid small molecule for the treatment of pain, resiniferatoxin (“RTX”), a first in its class (TRPV1 agonist ), and SP-102 (10 mg, sodium dexamethasone phosphate viscous gel) (SEMDEXA™), a novel viscous gel formulation of a corticosteroid widely used for epidural injections to treat lumbosacral radicular pain or sciatica, and to market ZTlido® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been approved for a Phase II trial for intractable cancer pain and a Phase II trial in patients with osteoarthritis. In March 2022, the final positive results of the CLEAR Program of the Pivotal Phase III Trial for SEMDEXA™, its novel non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced. ZTlido® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com

Forward-looking statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements regarding Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties. which could cause actual results to differ materially from those projected. Forward-looking statements include statements about the expectations of Sorrento and its subsidiaries’ candidate technologies and products. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements include, among others: risks related to technologies and prospects of Sorrento and its subsidiaries, affiliates and partners and collaborations with partners; risks related to seeking regulatory approvals and conducting clinical trials; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in executing its candidate product strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2021, and Quarterly Reports. subsequent filings on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in such filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Media and investor relations
Contact: Brian Cooley
Email: [email protected]

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVIMARK™, and Fujovee™ are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ (SP-102) is a trademark of Semnur Pharmaceuticals, Inc. FDA review of the proprietary name is pending.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

©2022 Sorrento Therapeutics, Inc. All rights reserved.

Leave a Comment